The Antibody Study

Currently Recruiting

1 Dec to 5 Dec 2025

Up to $5,250

The study drug is being developed to address the need for effective treatments for immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. IgAN is a condition where the immune system attacks the kidneys, leading to inflammation and potential kidney failure. 

Apply now Speak with us

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. 

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions. 

The study drug is being developed to address the need for effective treatments for immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. IgAN is a condition where the immune system attacks the kidneys, leading to inflammation and potential kidney failure. Current treatments for IgAN are limited and often not effective for all patients. 

The development of the study aims to provide a new therapeutic option that can effectively manage and potentially improve outcomes for patients with IgAN and other B cell-mediated diseases. 

Nucleus Network - Image

Why participate?

  • Contribute to Research that supports communities across the globe. 
  • Help Make Treatments More Inclusive and Effective 
  • Be the Reason Better Treatments Move Forward 

Trial details

Study medication

The study drug will be administered as subcutaneous (into or under your skin) injection

Ethics

An independent ethics committee has approved this clinical trial.

Additional eligibility

  • Weigh between 45kg and 110kg 
  • Non-smokers, or smoking no more than 2 cigarettes per day (or equivalent) no tobacco or nicotine use during the inpatient stay 
  • Prescription medications must be complete 7 days prior to admission (as discussed with our medical team) 
  • Must have completed influenza vaccination within 12 months prior to study drug administration. 
  • Must have completed Coronavirus disease 2019 (COVID-19) vaccination according to local guidelines or be willing to meet the requirement prior to study drug administration. 
  • No serious medical conditions  
  • Not pregnant or breastfeeding 
  • Willing to follow contraception guidelines (if applicable) 
  • Able to attend all study visits and follow instructions 

Study duration

4-night in-clinic stay and 5 follow-up visits

Are you a match?

Age

18 - 60 years old

Remuneration

Up to $5,250 *with screening reimbursement. Please see T&Cs.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

4 nights, 5 clinic visits

Register Your Interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact